Quality of life is lower in adults labeled with childhood-onset food allergy than in those with adult-onset food allergy

Patel, Gayatri; Kellner, Erinn S.; Clayton, Elisabeth; Chhiba, Krishan D.; Alakija, Omolola; Bryce, Paul J.; Wechsler, Joshua B.; Singh, Anne Marie

doi:10.1016/j.anai.2021.03.009

Cited by 12 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An American study found greater effects on QOL in adults whose food allergy presented in childhood, compared to those with onset in adulthood. 19 …”

Section: Discussionmentioning

confidence: 99%

“…An American study found greater effects on QOL in adults whose food allergy presented in childhood, compared to those with onset in adulthood. 19 There was a wide range for QOL impacts among individuals. Using the FAQLQ-AF questionnaire, the lowest possible score is 1 and highest is 7; there were some individuals within each domain and for each food allergen who scored at, or very close to, each end of the spectrum.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Phenotypic Distinctions Between Omega-5-Gliadin Allergy and Peanut Allergy: Clinical Profile, Reaction Rates and Triggers, and Quality of Life

Zubrinich¹,

Puy²,

O’Hehir³

et al. 2022

JAA

View full text Add to dashboard Cite

Background: Different phenotypes of food allergy may exist, exhibiting distinct clinical features, and driven by different pathogenic mechanisms. We compared omega-5-gliadin (O5G) allergy to peanut allergy, focusing on clinical features, reaction rates and triggers, and quality of life (QOL). Methods: We surveyed adults with O5G allergy and peanut allergy regarding their diagnosis, co-morbidities, allergic reactions, and QOL measured by the FAQLQ-AF. Results: We received responses from 43/80 (54%) individuals with O5G allergy and 43/130 (33%) with peanut allergy. Compared to peanut allergic individuals, those with O5G allergy were older at age of onset (37.2 vs 2.5 years, p < 0.001), had fewer additional atopic conditions (0.88 vs 2.93, p < 0.001) or food allergies (0.15 vs 1.86, p < 0.001), and more frequent reactions before diagnosis (1.085 vs 0.29 per month, p < 0.05) Reaction rates improved in both groups following diagnosis. Reactions to peanut were more often triggered by accidental exposure (84% vs 26%, p < 0.001) and being away from home (65% vs 28%, p < 0.001), while reactions to O5G were more often due to deliberate ingestion (30% vs 9%, p < 0.05) or unexpected exercise (35% vs 2%, p < 0.001). Overall QOL score was similar between groups (4.2 in O5G allergy, 4.7 in peanut allergy, p = 0.12), but worse among women and those with additional food allergies. Conclusion: Phenotypic differences between O5G and peanut allergy support the development of different clinical approaches and the possibility of targeting distinct pathogenic mechanisms for prevention and treatment. Quality of life was impaired to a similar degree between groups.

show abstract

“…An American study found greater effects on QOL in adults whose food allergy presented in childhood, compared to those with onset in adulthood. 19 …”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Phenotypic Distinctions Between Omega-5-Gliadin Allergy and Peanut Allergy: Clinical Profile, Reaction Rates and Triggers, and Quality of Life

Zubrinich¹,

Puy²,

O’Hehir³

et al. 2022

JAA

View full text Add to dashboard Cite

show abstract

“…There is increasing evidence that patients managing food allergy, and their families, face notable intangible costs. For example, these families report significantly lower health-related quality of life [2][3][4][5], a construct that appears to be driven by differences in anxiety. Indeed, a recent review supports that food allergy anxiety is a different construct than healthrelated quality of life [6].…”

Section: Introductionmentioning

confidence: 99%

The Indirect Costs of Avoidance in Food Allergy Management: A Scoping Review

Protudjer,

Engel

2024

Allergies

View full text Add to dashboard Cite

Background: Food allergy management requires avoidance of allergenic food. While the direct costs of food allergy management have been described, avoidance may also contribute to time and opportunity costs. We aimed to conduct a scoping review of the peer-reviewed literature on the indirect costs of food allergy, and to characterise these costs through a series of fictitious case studies. Methods: We performed a scoping review, guided by Arskey and O’Malley’s methodological framework, and reported using the Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews. Eligible studies included original, peer-reviewed, English language literature with no lower limits to publication dates, which addressed the indirect costs of food allergy, including time and opportunity costs. A search strategy was developed by content experts with experience performing multi-database scoping reviews. The search was performed on 10 July 2023, managed using Rayyan (Cambridge, USA), and screened for eligibility. Results: Searches yielded 104 articles. After deduplication, 96 articles were screened at the title and abstract level; 12 articles were included following full-text screening. Of these, three studies were performed on adults with food allergy, eight studies were based on data collected from caregivers of children with food allergy, and one study made use of data reflecting adults and caregivers of children with food allergy. Collectively, indirect costs were identified as higher amongst those with vs. without food allergy. The few studies on age and food allergy differences (e.g., type and number of food allergies, history of reaction) are equivocal. Conclusions: The limited body of peer-reviewed literature supports that food allergy commonly carries substantial indirect costs across diverse measurement tools, albeit with age-group differences.

show abstract

“…diagnostics, food allergy, oral immunotherapy, prevention, treatment FA additionally presents with significant impacts to quality of life 6,7 and a high economic burden. 8 While the first approved treatment for peanut allergy (PA) is now available, 9 the current standard of care for other food allergens remains strict avoidance.…”

Section: Introductionmentioning

confidence: 99%

“…In the US, using cross‐sectional population‐based surveys, FA prevalence has been estimated at approximately 8% in children and 11% in adults 2,3 ; In Europe, using data from the EuroPrevall‐iFAAM birth cohort, prevalence in children was found to be much lower at 1.4–3.8% 4,5 . FA additionally presents with significant impacts to quality of life 6,7 and a high economic burden 8 . While the first approved treatment for peanut allergy (PA) is now available, 9 the current standard of care for other food allergens remains strict avoidance.…”

Section: Introductionmentioning

confidence: 99%

Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi‐targeted approach

Sindher

Long

Chin

et al. 2022

Allergy

View full text Add to dashboard Cite

The incidence of food allergy (FA) has continued to rise over the last several decades, posing significant burdens on health and quality of life. Significant strides into the advancement of FA diagnosis, prevention, and treatment have been made in recent years. In an effort to lower reliance on resource‐intensive food challenges, the field has continued work toward the development of highly sensitive and specific assays capable of high‐throughput analysis to assist in the diagnosis FA. In looking toward early infancy as a critical period in the development of allergy or acquisition of tolerance, evidence has increasingly suggested that early intervention via the early introduction of food allergens and maintenance of skin barrier function may decrease the risk of FA. As such, large‐scale investigations are underway evaluating infant feeding and the impact of emollient and steroid use in infants with dry skin for the prevention of allergy. On the other end of the spectrum, the past few years have been witness to an explosive increase in clinical trials of novel and innovative therapeutic strategies aimed at the treatment of FA in those whom the disease has already manifested. A milestone in the field, 2020 marked the approval of the first drug, oral peanut allergen, for the indication of peanut allergy. With a foundation of promising data supporting the safety and efficacy of single‐ and multi‐allergen oral immunotherapy, current efforts have turned toward the use of probiotics, biologic agents, and modified allergens to optimize and improve upon existing paradigms. Through these advancements, the field hopes to gain footing in the ongoing battle against FA.

show abstract

Quality of life is lower in adults labeled with childhood-onset food allergy than in those with adult-onset food allergy

Cited by 12 publications

References 23 publications

Phenotypic Distinctions Between Omega-5-Gliadin Allergy and Peanut Allergy: Clinical Profile, Reaction Rates and Triggers, and Quality of Life

Phenotypic Distinctions Between Omega-5-Gliadin Allergy and Peanut Allergy: Clinical Profile, Reaction Rates and Triggers, and Quality of Life

The Indirect Costs of Avoidance in Food Allergy Management: A Scoping Review

Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi‐targeted approach

Contact Info

Product

Resources

About